title: Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.
abstract: NS3 protease inhibitors are set to improve sustained virological response rates in HIV-positive patients with hepatitis C. We measured the prevalence of natural resistance polymorphisms in 38 acutely infected treatment-naive patients using direct and deep sequencing. Twenty six percent of patients (10/38) had a majority variant resistance mutation (in order of frequency; Q80K - 16%, V36M - 5%, T54S - 3%, V55A - 3%, and D168A - 3%). Low-frequency mutations were detected in all samples. Further studies are required to determine threshold levels associated with treatment failure.
authors.affiliation: aMRC Centre for Virus Research, University of Glasgow, Glasgow bDepartment of Virology, Imperial College NHS Trust cDepartment of Medicine, Imperial College London, London, UK.
authors.forename: Mayke
authors.initials: M
authors.lastname: Leggewie
authors.forename: Vattipally B
authors.initials: VB
authors.lastname: Sreenu
authors.forename: Tamer
authors.initials: T
authors.lastname: Abdelrahman
authors.forename: E Carol M
authors.initials: EC
authors.lastname: Leitch
authors.forename: Gavin S
authors.initials: GS
authors.lastname: Wilkie
authors.forename: Tetyana
authors.initials: T
authors.lastname: Klymenko
authors.forename: David
authors.initials: D
authors.lastname: Muir
authors.forename: Mark
authors.initials: M
authors.lastname: Thursz
authors.forename: Janice
authors.initials: J
authors.lastname: Main
authors.forename: Emma C
authors.initials: EC
authors.lastname: Thomson
mesh_terms: D000208:Acute Disease; D015658:HIV Infections / Q000150:complications; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000235:genetics*; D006801:Humans; D011110:Polymorphism, Genetic / Q000235:genetics*; D012367:RNA, Viral / Q000235:genetics*
chemical_list: D012367:RNA, Viral